AIC. Dynavax
- PMID: 12833657
AIC. Dynavax
Abstract
Dynavax is developing Amb a 1 immunostimulatory oligodeoxynucleotide-conjugate (AIC) as a potential immunotherapy for ragweed-induced seasonal allergy. By May 2001, phase II/III trials were underway in Canada and the US, and by March 2002, phase II trials were underway in France. In October 2002, Dynavax expected to commence a phase III trial in 2003.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical